Printer Friendly

CELLEGY REPORTS PHASE II CLINICAL TRIAL RESULTS OF GLYLORIN(TM) FOR ORPHAN DRUG DESIGNATED INDICATION, CONGENITAL ICHTHYOSIS

 NOVATO, Calif., Sept. 7 /PRNewswire/ -- Cellegy Pharmaceuticals Inc. today announced the completion of a Phase II dose-ranging study of Glylorin(TM) (monolaurin) in patients with congenital ichthyosis erythroderma (CIE). The data substantiates the positive results of previous studies and demonstrated a dose response and statistically significant improvement over a placebo vehicle.
 The study was conducted at Yale University and at the University of California, San Francisco Medical Center.
 Patients with CIE participated in the six-week, randomized, double- blind, placebo-controlled study. There was clear dose-related improvement and no adverse events were reported.
 "The positive results of this study support Cellegy's belief that Glylorin(TM) may be a powerful tool for the physician to use with patients suffering from this disfiguring disease," noted Gerald Simmons, president and chief executive officer of Cellegy. "More important, these results help validate Cellegy's unique scientific approach to dermatological drug development."
 Glylorin(TM) recently was designated an orphan drug by the Food and Drug Administration (FDA). Cellegy plans to file a new drug application (NDA) with the FDA in 1994.
 Congenital ichthyosis, which includes CIE, is a debilitating disease characterized by dry, thickened, scaling skin. Currently, there is no prescription drug indicated for this condition.
 Cellegy focuses on the role the epidermis plays in regulating skin physiology and disease. The company's research shows that the outermost layer of skin, the stratum corneum, is active metabolically and possesses the ability to stimulate the release of biological response modifiers. This understanding, coupled with the discovery of certain compounds with the potential for therapeutic activity has created the basis for Cellegy's product development programs.
 Cellegy Pharmaceuticals Inc. is a privately held biopharmaceutical company developing dermatological products to treat and prevent skin disorders and chronic skin diseases, to minimize the effects of aging, and deliver large molecular weight drugs.
 -0- 9/7/93
 /CONTACT: Gerald Simmons, president and CEO, Cellegy Pharmaceuticals, 415-382-6770; or Kimberly Kraemer or Mark Brand, Pondel Parsons & Wilkinson, 310-207-9300/


CO: Cellegy Pharmaceuticals Inc. ST: California IN: MTC SU:

JL-LM -- LA011 -- 9260 09/07/93 10:32 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 7, 1993
Words:339
Previous Article:HOME SAVINGS OF AMERICA COMPLETES ACQUISITION OF 10 BRANCHES OF LONG ISLAND SAVINGS BANK
Next Article:UPCOMING MAZDA MID-SIZE LUXURY SEDAN TO BE NAMED 'MILLENIA'
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters